![Lung cancer / Clinical medicine / Cancer / Tyrosine kinase inhibitors / Boehringer Ingelheim / Health / T790M / Protein kinase inhibitor / Epidermal growth factor receptor / Non-small-cell lung carcinoma / Targeted therapy Lung cancer / Clinical medicine / Cancer / Tyrosine kinase inhibitors / Boehringer Ingelheim / Health / T790M / Protein kinase inhibitor / Epidermal growth factor receptor / Non-small-cell lung carcinoma / Targeted therapy](https://www.pdfsearch.io/img/79dcd1b24af70083a47bbe0759ac56a5.jpg) Date: 2015-11-24 01:50:17Lung cancer Clinical medicine Cancer Tyrosine kinase inhibitors Boehringer Ingelheim Health T790M Protein kinase inhibitor Epidermal growth factor receptor Non-small-cell lung carcinoma Targeted therapy | | ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced Add to Reading ListSource URL: www.zailaboratory.comDownload Document from Source Website File Size: 225,61 KBShare Document on Facebook
|